{"disease":{"id":"myeloproliferative-neoplasms","name":"myeloproliferative neoplasms"},"drugs":{"marketed":[{"drug_id":"part-c-met097","indication_name":"Treatment of Myeloproliferative Neoplasms (MPNs)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of myeloproliferative neoplasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT02252159","title":"Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)","phase":"","overall_status":"COMPLETED","enrollment_count":2544,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02953704","title":"Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)","phase":"","overall_status":"COMPLETED","enrollment_count":1469,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07410247","title":"MPN Childhood Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT03618485","title":"Registry of Patients With MPNs in Taiwan","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06034002","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06740916","title":"Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT05936359","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07441694","title":"Study of INCA036978 in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":218,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02393248","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":201,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06313593","title":"A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07150468","title":"Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT07008118","title":"A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT01520220","title":"Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT01633372","title":"An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07384039","title":"Exercise Training in Patients With Myeloproliferative Neoplasms","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Hannover Medical School","has_results":false},{"nct_id":"NCT06753279","title":"Clinical Significance of Leukocyte Cell Population Data in Patients With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT02718300","title":"A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04113616","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01348490","title":"Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06270771","title":"OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Sunnybrook Health Sciences Centre","has_results":false},{"nct_id":"NCT05782985","title":"Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs","phase":"","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04339400","title":"A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT03011372","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT01393509","title":"The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06597734","title":"A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03912064","title":"A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT03144687","title":"A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03075826","title":"A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT07071155","title":"Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT05444530","title":"A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03123588","title":"Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04866056","title":"Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}